Preclinical characterization of CPL304110 as a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3 for gastric, bladder, and squamous cell lung cancer

Overview of attention for article published in Frontiers in oncology, January 2024

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Good Attention Score compared to outputs of the same age and source (68th percentile)

Mentioned by

twitter: 3 X users

Readers on

mendeley: 2 Mendeley

Summary X

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 36,431 followers.

RT @DrImranSheikh: Preclinical characterization of CPL304110 as a potent and selective inhibitor of fibroblast growth factor receptors 1, 2…

18 Jan 2024

Reply Repost Favourite

Preclinical characterization of CPL304110 as a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3 for gastric, bladder, and squamous cell lung cancer: Fibroblast Growth Factor Receptors (FGFRs) are a…… #oncology https://t.co/

18 Jan 2024

Reply Repost Favourite

New research: Preclinical characterization of CPL304110 as a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3 for gastric, bladder, and squamous cell lung cancer: Fibroblast Growth Factor Receptors (FGFRs) are a… https://t.c

13 Jan 2024

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.